---
document_datetime: 2025-12-16 09:57:42
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/ventavis-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: ventavis-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.3653713
conversion_datetime: 2025-12-28 12:15:27.268699
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Ventavis

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | C.I.11 Introduction of, or change(s) to, the | 11/12/2025                          | N/A                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000309744                     | obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Other obligations and conditions (e.g. agreed wording + QRD template) - Accepted To update RMP for Ventavis to remove the use of Iloprost specific Targeted Follow-up Questionnaire to collect additional information for reports of LRTI and remove LRTI from the list of safety concerns as an PRAC outcome from the PSUSA procedure EMEA/H/C/PSUSA/00001724/202309 recommendation.                                                       |            |     |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IA / EMA/VR/0000261914 | This was an application for a group of variations. B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.b Tightening of specification limits - Accepted B.III.2.a Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - B.III.2.a.2 Excipient/active substance starting material - Accepted | 31/03/2025 | N/A |